
Opinion|Videos|December 8, 2023
A Review of 3L+ Treatments for DLBCL
Author(s)Matthew A. Lunning, DO, FACP
A comprehensive overview of third-line relapsed/refractory DLBCL treatment options, including CAR T-cell therapy and bispecific antibodies.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5

































